The effect of angiotensin-converting enzyme inhibitors and statins on the progression of aortic sclerosis and mortality

Journal of Heart Valve Disease

Volumn 21, Issue 3, 2012, Pages 337-343

  Ardehali, Reza ^a   Leeper, Nicholas J ^b,c   Wilson, Andrew M ^b,c   Heidenreich, Paul A ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; AORTA ATHEROSCLEROSIS; ARTICLE; CARDIOVASCULAR MORTALITY; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DISEASE COURSE; DRUG EFFECT; FEMALE; HEART HEMODYNAMICS; HOSPITALIZATION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; TRANSTHORACIC ECHOCARDIOGRAPHY; AORTA DISEASE; AORTA VALVE STENOSIS; ATHEROSCLEROSIS; CHRONIC DISEASE; COMORBIDITY; ECHOCARDIOGRAPHY; HEMODYNAMICS; METHODOLOGY; MORTALITY; PATHOPHYSIOLOGY; QUALITY ADJUSTED LIFE YEAR; SECONDARY PREVENTION; TREATMENT OUTCOME;

AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; AORTIC DISEASES; AORTIC VALVE STENOSIS; ATHEROSCLEROSIS; CHRONIC DISEASE; COMORBIDITY; DISEASE PROGRESSION; ECHOCARDIOGRAPHY; FEMALE; HEMODYNAMICS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; QUALITY-ADJUSTED LIFE YEARS; SECONDARY PREVENTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84866012058     PISSN: 09668519     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Stewart BF, Siscovick D, Lind BK, et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol 1997;29:630-634
2. Peltier M, Trojette F, Sarano ME, Grigioni F, Slama MA, Tribouilloy CM. Relation between cardiovascular risk factors and nonrheumatic severe calcific aortic stenosis among patients with a three-cuspid aortic valve. Am J Cardiol 2003;91:97-99
3. O'Brien KD. Pathogenesis of calcific aortic valve disease: A disease process comes of age (and a good deal more). Arterioscler Thromb Vasc Biol 2006;26:1721-1728
4. Otto CM, Lind BK, Kitzman DW, Gersh BJ, Siscovick DS. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med 1999;341:142-147
5. Palta S, Pai AM, Gill KS, Pai RG. New insights into the progression of aortic stenosis: Implications for secondary prevention. Circulation 2000;101:2497-2502
6. Baigent C, Keech A, Kearney PM, et al. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-1278
7. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-788
8. Otto CM. Valvular aortic stenosis: Disease severity and timing of intervention. J Am Coll Cardiol 2006;47:2141-2151
9. O'Brien KD, Probstfield JL, Caulfield MT, et al. Angiotensin-converting enzyme inhibitors and change in aortic valve calcium. Arch Intern Med 2005;165:858-862
10. Newby DE, Cowell SJ, Boon NA. Emerging medical treatments for aortic stenosis: Statins, angiotensin converting enzyme inhibitors, or both? Heart 2006;92:729-734
11. .Moura LM, Ramos SF, Zamorano JL, et al. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol 2007;49:554-561
12. Jimenez-Candil J, Bermejo J, Yotti R, et al. Effects of angiotensin converting enzyme inhibitors in hypertensive patients with aortic valve stenosis: A drug withdrawal study. Heart 2005;91:1311-1318
13. Rosenhek R, Rader F, Loho N, et al. Statins but not angiotensin- converting enzyme inhibitors delay progression of aortic stenosis. Circulation 2004;110:1291-1295
14. Cowell SJ, Newby DE, Prescott RJ, et al. Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression (SALTIRE) Investigators. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 2005;352:2389-2397
15. Danilczyk U, Penninger JM. Angiotensin-converting enzyme II in the heart and the kidney. Circ Res 2006;98:463-471
16. Gotto AM. Review of primary and secondary prevention trails with lovastatin, pravastatin, and simvastatin. Am J Cardiol 2005;96:34F-38F
17. Goldbarg SH, Elmariah S, Miller MA, Fuster V. Insights into degenerative aortic valve disease. J Am Coll Cardiol 2007;50:1205-1213
18. O'Brien KD, Shavelle DM, Caulfield MT, et al. Association of angiotensin-converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma. Circulation 2002;106:2224-2230
19. Helske S, Lindstedt KA, Laine M, et al. Induction of local angiotensin II-producing systems in stenotic aortic valves. J Am Coll Cardiol 2004;44:1859-1866
20. Pohle K, Maffert R, Ropers D, et al. Progression of aortic valve calcification: Association with coronary atherosclerosis and cardiovascular risk factors. Circulation 2001;104:1927-1932
21. Aronow WS, Ahn C, Kronzon I, Goldman ME. Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons. Am J Cardiol 2001;88:693-695
22. Novaro GM, Tiong IY, Pearce GL, Lauer MS, Sprecher DL, Griffin BP. Effect of hydroxymethylglutaryl coenzyme A reductase inhibitors on the progression of calcific aortic stenosis. Circulation 2001;104:2205-2209
23. Shavelle DM, Takasu J, Budoff MJ, Mao S, Zhao XQ, O'Brien KD. HMG CoA reductase inhibitor (statin) and aortic valve calcium. Lancet 2002;359:1125-1126
24. Bellamy MF, Pellikka PA, Klarich KW, Tajik AJ, Enriquez-Sarano M. Association of cholesterol levels, hydroxymethylglutaryl coenzyme-A reductase inhibitor treatment, and progression of aortic stenosis in the community. J Am Coll Cardiol 2002;40:1723-1730
25. Rossebø AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008;359:1343-1356
26. Chan KL, Teo K, Dumesnil JG, Ni A, Tam J; ASTRONOMER Investigators. Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: Results of the aortic stenosis progression observation: Measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation 2010;121:306-314